Ticker Details
Corvus Pharmaceuticals, Inc. Common Stock Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It is engaged in development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells.
IPO Date:	March 21, 2016
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.22B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.23 | 4.14%
Avg Daily Range (30 D):	$0.41 | 2.82%
Avg Daily Range (90 D):	$0.47 | 3.33%

Institutional Daily Volume
Avg Daily Volume:	.66M
Avg Daily Volume (30 D):	.69M
Avg Daily Volume (90 D):	1.11M

Trade Size
Avg Trade Size (Sh.):	163
Avg Trade Size (Sh.) (30 D):	55
Avg Trade Size (Sh.) (90 D):	67

Institutional Trades
Total Institutional Trades:	456
Avg Institutional Trade:	$1.96M
Avg Institutional Trade (30 D):	$2.04M
Avg Institutional Trade (90 D):	$2.32M
Avg Institutional Trade Volume:	.19M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.64M
Avg Closing Trade (30 D):	$2.08M
Avg Closing Trade (90 D):	$2.68M
Avg Closing Volume:	227.47K

News

Jun 23, 2026 @ 7:20 PM Corvus Pharmaceuticals Director Buys 21,700 Shares... Source: Brendan Coffey

Apr 27, 2026 @ 5:00 PM Peripheral T-Cell Lymphoma Market to Witness Signi... Source: Delveinsight

Feb 2, 2026 @ 5:48 PM Momentum Is Just Starting for These 3 Rapid-Growth... Source: Nathan Reiff

Jan 23, 2026 @ 10:00 PM Corvus Pharmaceuticals Announces Closing of Upsize... Source: Corvus Pharmaceuticals, Inc.

Jan 22, 2026 @ 3:53 AM Corvus Pharmaceuticals Announces Pricing of Upsize... Source: Na

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-.62	$-.19	$-.15
Diluted EPS	$-.62	$-.19	$-.15
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-54.13M	$-17.96M	$-13.69M
Operating Income / Loss	$-56.96M	$-19.3M	$-14.88M
Cost of Revenue
Net Cash Flow	$4.21M	$-21.2M	$35.53M
PE Ratio